Here's Why Pfizer Should Buy GlaxoSmithKline

The same benefits Pfizer wanted out of AstraZeneca--a boosted pipeline and international exposure--could be had from Glaxo, along with a strong consumer franchise that Pfizer lacks.

Jul 8, 2014 at 9:00AM

In the aftermath of pharmaceutical giant Pfizer (NYSE:PFE) failing in its repeated attempts to acquire European drug maker AstraZeneca (NYSE:AZN), investors may be wondering what's next. After all, Pfizer's enormous offer and seeming willingness to pay quite a premium to no avail has left a bit of egg on management's face.

In its post-Lipitor era, organic growth has been hard to come by. And, since taking new drugs all the way to market is an extremely costly and time-consuming effort, management probably feels the easiest way to get the growth it needs now is by buying up a rival company.

Now that Pfizer has been rejected by AstraZeneca, it would be a mistake for the company to end its pursuits. The fundamental challenges facing the company, namely its severe patent losses, still remain. Since AstraZeneca is now off the table, Pfizer should bid for another U.K.-based pharmaceutical giant: GlaxoSmithKline (NYSE:GSK).

Going abroad for growth
To try to reenergize growth in its pipeline and in new overseas markets, Pfizer made several offers for AstraZeneca. AstraZeneca wouldn't budge, and now Pfizer is left by its lonesome.

Pfizer still faces tough patent expirations that continue to drag down the company's financial performance. Pfizer is enduring expiration on collaboration agreements of other key drugs, including Enbrel in the United States and Canada, as well as Spiriva in certain countries, and multi-source generic competition for Detrol LA, that are weighing on the top and bottom lines.

It's because of ongoing expirations that Pfizer's revenue fell 9%, or $1.1 billion, last quarter. This was due primarily to a 10% drop in its established pharmaceutical segment. Meanwhile, earnings per share fell 5% in the quarter.

GlaxoSmithKline can answer many of Pfizer's key questions. Glaxo is doing very well in emerging markets. Its pharmaceuticals and vaccines segment posted 2% sales growth in emerging markets and 13% sales growth in Japan last quarter.

In addition, Glaxo has a robust pipeline in some exciting new areas of therapy. For example, its HIV sales rose 4% last quarter thanks to the recent launch of integrase inhibitor Tivicay. In all, Glaxo holds 40 new molecular entities in either phase 2 or 3 clinical development.

However, it's worth noting Glaxo faces its own challenges. Sales in its pharmaceuticals and vaccines segment fell 10% in the U.S., mostly because of generic competition to its key drug Advair. Advair sales fell 30%, which matters a lot since it makes up about 30% of its respiratory sales.

At the same time, Glaxo is counting on recently launched COPD treatments Breo and Anoro take up some of the slack in its respiratory portfolio.

The vaccine portfolio will be helped greatly since Glaxo purchased the global vaccines business of Novartis earlier this year for $5.25 billion. The transaction is expected to be immediately accretive to Glaxo's EPS. In particular, Glaxo management is excited about the meningitis drug Bexsero.

Glaxo also has a strong consumer business, led by popular brands such as Aquafresh, Nicorette, and Tums. Pfizer doesn't have much of a consumer business to speak of, since it derived just 6% of its sales from consumer health care last quarter.

What Glaxo can offer Pfizer right now is clear. Pfizer expects full-year revenue to decline as much as 5% and flat earnings, while Glaxo projects modest sales growth and 6% earnings growth.

The Foolish bottom line
In summary, many of the same benefits Pfizer sought from AstraZeneca, including a favorable tax structure and a rebuilt pipeline, could be had with Glaxo as well. In addition, Pfizer would also receive the benefit of an expanded consumer health care business, which it currently doesn't have. It seems that Pfizer management intends on shifting the company toward being a nearly pure-play on pharmaceuticals, but that could be a double-edged sword.

The potential for blockbusters is compelling, but it's also a riskier pursuit than some of the diversified health care companies. Bringing Glaxo's established consumer brands and vaccine segments in might not seem sexy, but they would provide a valuable dose of consistency to Pfizer's financial performance, which has been fairly volatile over the past several quarters.

But why worry about Glaxo and Astra when there is an even bigger opportunity?
The best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Bob Ciura has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers